Pesquisas alternativas:
"esto open" » "tests open" (Expandir a Pesquisa), "oto open" (Expandir a Pesquisa), "esto en" (Expandir a Pesquisa), "estdo open" (Expandir a Pesquisa), "estao open" (Expandir a Pesquisa), "esto opens" (Expandir a Pesquisa)
"gesto en" » "gesto e" (Expandir a Pesquisa), "gesto de" (Expandir a Pesquisa), "gesto y" (Expandir a Pesquisa)
"eo open" » "do open" (Expandir a Pesquisa), "ao open" (Expandir a Pesquisa), "so open" (Expandir a Pesquisa), "edo open" (Expandir a Pesquisa), "eao open" (Expandir a Pesquisa), "eo opens" (Expandir a Pesquisa)
"esmo open" » "esmdo open" (Expandir a Pesquisa), "esmao open" (Expandir a Pesquisa), "esmo opens" (Expandir a Pesquisa), "eso open" (Expandir a Pesquisa), "ecmo open" (Expandir a Pesquisa), "esko open" (Expandir a Pesquisa)
"o open" » "do open" (Expandir a Pesquisa), "ao open" (Expandir a Pesquisa), "o opens" (Expandir a Pesquisa)
A mostrar 141 - 160 resultados de 473 para a pesquisa '(((("eo open") OR ((("esmo open") OR ((("esto open") OR ("gesto en"))))))) OR ("o open"))', tempo de pesquisa: 1.65seg Refinar resultados
Quality to rely on: meeting report of the 5th Meeting of External Quality Assessment, Naples 2016
Nutrition in patients with cancer: a new area for medical oncologists? A practising oncologist’s interdisciplinary position paper

The ESMO/ASCO Global Curriculum and the evolution of medical oncology training in Europe
Clonal evolution and KRAS-MET coamplification during secondary resistance to EGFR-targeted therapy in metastatic colorectal cancer

Challenge of implementing clinical practice guidelines. Getting ESMO’s guidelines even closer to the bedside: introducing the ESMO Practising Oncologists’ checklists and knowledge and practice questions
Time since start of first-line therapy as a predictive clinical marker for nintedanib in patients with previously treated non-small cell lung cancer

Tumour-infiltrating lymphocytes are correlated with higher expression levels of PD-1 and PD-L1 in early breast cancer
A consensus on liquid biopsy from the 2016 Chinese Lung Cancer Summit expert panel

Safety and activity of IT-139, a ruthenium-based compound, in patients with advanced solid tumours: a first-in-human, open-label, dose-escalation phase I study with expansion cohort
Clinical outcome and molecular characterisation of chemorefractory metastatic colorectal cancer patients with long-term efficacy of regorafenib treatment

Precision oncology: separating the wheat from the chaff
Phase I study of neoadjuvant chemotherapy with S-1 and oxaliplatin for locally advanced gastric cancer (Neo G-SOX PI)

Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinoma
Recent developments and translational aspects in targeted therapy for metastatic breast cancer

KRAS-driven lung adenocarcinoma: combined DDR1/Notch inhibition as an effective therapy
ESMO gave me a chance to help make a difference: a personal reflection on the occasion of receiving the 2015 ESMO Award

CECOG educational illustrations: the blood–brain barrier and its relevance for targeted cancer therapies and immuno-oncology
Recent advances in the biology and treatment of brain metastases of non-small cell lung cancer: summary of a multidisciplinary roundtable discussion

2018 ESMO Sarcoma and GIST Symposium: ‘take-home messages’ in soft tissue sarcoma
Health-related quality of life in a randomised phase III study of gemcitabine plus S-1, S-1 alone and gemcitabine alone for locally advanced or metastatic pancreatic cancer: GEST study

Ferramentas de pesquisa: Obter Feed RSS — Enviar pesquisa por email — Guardar a pesquisa